These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893 [TBL] [Abstract][Full Text] [Related]
3. Unraveling the epigenetic code of cancer for therapy. Smith LT; Otterson GA; Plass C Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396 [TBL] [Abstract][Full Text] [Related]
4. A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation. Reamon-Buettner SM; Borlak J Reprod Toxicol; 2007 Jul; 24(1):20-30. PubMed ID: 17596910 [TBL] [Abstract][Full Text] [Related]
5. Epigenetic alterations and cancer: new targets for therapy. Allen A IDrugs; 2007 Oct; 10(10):709-12. PubMed ID: 17899489 [TBL] [Abstract][Full Text] [Related]
7. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. Dobosy JR; Roberts JL; Fu VX; Jarrard DF J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic mechanisms in AML - a target for therapy. Oki Y; Issa JP Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243 [TBL] [Abstract][Full Text] [Related]
10. The clinical application of targeting cancer through histone acetylation and hypomethylation. Gilbert J; Gore SD; Herman JG; Carducci MA Clin Cancer Res; 2004 Jul; 10(14):4589-96. PubMed ID: 15269129 [TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Teodoridis JM; Strathdee G; Brown R Drug Resist Updat; 2004; 7(4-5):267-78. PubMed ID: 15533764 [TBL] [Abstract][Full Text] [Related]
13. Epigenetics, disease, and therapeutic interventions. Lu Q; Qiu X; Hu N; Wen H; Su Y; Richardson BC Ageing Res Rev; 2006 Nov; 5(4):449-67. PubMed ID: 16965942 [TBL] [Abstract][Full Text] [Related]
14. DNA methylomes, histone codes and miRNAs: tying it all together. Guil S; Esteller M Int J Biochem Cell Biol; 2009 Jan; 41(1):87-95. PubMed ID: 18834952 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic biomarkers for human cancer: the time is now. Mulero-Navarro S; Esteller M Crit Rev Oncol Hematol; 2008 Oct; 68(1):1-11. PubMed ID: 18430583 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. Li LC; Carroll PR; Dahiya R J Natl Cancer Inst; 2005 Jan; 97(2):103-15. PubMed ID: 15657340 [TBL] [Abstract][Full Text] [Related]
17. [Epigenome and cancer: new possibilities of cancer prevention and therapy?]. Paluszczak J; Baer-Dubowska W Postepy Biochem; 2005; 51(3):244-50. PubMed ID: 16381168 [TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Grønbaek K; Treppendahl M; Asmar F; Guldberg P Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):389-96. PubMed ID: 18947362 [TBL] [Abstract][Full Text] [Related]
19. DNA methylation and histone modifications in patients with cancer: potential prognostic and therapeutic targets. Herranz M; Esteller M Methods Mol Biol; 2007; 361():25-62. PubMed ID: 17172706 [TBL] [Abstract][Full Text] [Related]
20. [Epigenetics and cancer]. Kern I; Rossier MF; Chappuis PO Rev Med Suisse; 2007 Feb; 3(100):540-2, 544-5. PubMed ID: 17410941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]